Saudi Journal of Gastroenterology

: 2013  |  Volume : 19  |  Issue : 5  |  Page : 240--241

Helicobacter pylori in the era of probiotics: A controversial application

Amin T.B Abadi1, Ashraf M Mobarez2, Fatemeh H.A Tabrizi3,  
1 Department of Medical Microbiology, Utrecht University, Utrecht, Netherlands
2 Department of Bacteriology, School of Medical Sciences, Tarbiat Modares University, Tehran, Iran
3 Department of Biology, Kharazmi University, Karaj, Iran

Correspondence Address:
Amin T.B Abadi
Department of Medical Microbiology, Utrecht University, Utrecht

How to cite this article:
Abadi AT, Mobarez AM, Tabrizi FH. Helicobacter pylori in the era of probiotics: A controversial application.Saudi J Gastroenterol 2013;19:240-241

How to cite this URL:
Abadi AT, Mobarez AM, Tabrizi FH. Helicobacter pylori in the era of probiotics: A controversial application. Saudi J Gastroenterol [serial online] 2013 [cited 2020 Oct 27 ];19:240-241
Available from:

Full Text


Owing to the increased rate of resistance among the Helicobacter pylori strains, the efficacy of the prescribed antibiotics has reduced globally. [1] Consequently, alternative approaches can be an option to overcome this unsolved issue in clinical trials. [2] Probiotics, as a living bacterium in gastrointestinal routes, which provides health benefits has been called as a potential candidate. Recently, several studies investigated the efficacy of different probiotics in experimental and large scale levels. Recently, Dajani et al., proposed Bifidobacterium infantis as a preferable adjuvant for several therapeutic regimens used to eradicate the H. pylori infection. [3] Although probiotic therapy as an adjuvant had been reported to be an effective approach for treatment of H. pylori, the exact mechanism is not clearly elucidated yet. Moreover, the success of each of the three investigated therapeutic regimens in study by Dajani et al., need to be evaluated separately. [2] In other words, prescription of probiotic (B. infantis) in H. pylori therapeutic regimens should be compared with particular negative control group. In other words, adding a probiotic (B. infantis) should be recommended under assumption of independent factors, including various treatment regimens. Altogether, the current findings should be recommended to clinicians with caution. Meanwhile, the current data by Dajani et al., can be a good pilot, which will be encouraging for other groups in the aforementioned area to disclose further interesting findings for drawing a comprehensive conclusion.


1Talebi Bezmin Abadi A, Mobarez AM, Taghvaei T, Wolfram L. Antibiotic resistance of Helicobacter pylori in Mazandaran, North of Iran. Helicobacter 2010;15:505-9.
2Baryshnikova NV. Helicobacter pylori-associated gastroenterological diseases: Genetic features and probiotic treatment. Benef Microbes 2012;3:157-61.
3Dajani AI, Abu Hammour AM, Yang DH, Chung PC, Nounou MA, Yuan KY, et al. Do probiotics improve eradication response to Helicobacter pylori on standard triple or sequential therapy? Saudi J Gastroenterol 2013;19:113-20.